Michael Ong
Ottawa Hospital Research Institute, Ottawa ON Canada · Ottawa Hospital Research Institute · Ottawa Hospital Research Institute, Ottawa, ON Canada
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Ong as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:52 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06592924 · Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseCanadian Cancer Trials Group · recruiting · Prostate Cancer (Adenocarcinoma) · study chair
- Ph2NCT04543110 · Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBCOttawa Hospital Research Institute · unknown · Bladder Cancer · principal investigator
- Ph2NCT03385655 · Prostate Cancer Biomarker Enrichment and Treatment SelectionCanadian Cancer Trials Group · active not recruiting · Prostate Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 69 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:52 UTC. The ranking covers the 200 most relevant of 102 PubMed records, and a shared surname and initials can bring in a namesake. All 102 on PubMed
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.JAMA Oncol · 2017726 citationsRCR 22.6
- 540 citationsRCR 22.2
- 195 citationsRCR 7.8
- Community-partnered cluster-randomized comparative effectiveness trial of community engagement and planning or resources for services to address depression disparities.J Gen Intern Med · 2013162 citationsRCR 7.3
- Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.Diabetologia · 1998157 citationsRCR 4.1
- Antitumor activity in RAS-driven tumors by blocking AKT and MEK.Clin Cancer Res · 2015123 citationsRCR 3.1
- Healthcare worker stress, anxiety and burnout during the COVID-19 pandemic in Singapore: A 6-month multi-centre prospective study.PLoS One · 2021119 citationsRCR 12.8
- Supervised home-based exercise may attenuate the decline of glucose tolerance in obese pregnant women.Diabetes Metab · 200982 citationsRCR 3.1
- OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.Clin Cancer Res · 202178 citationsRCR 3.4
- A before-after interventional trial of dispatcher-assisted cardio-pulmonary resuscitation for out-of-hospital cardiac arrests in Singapore.Resuscitation · 201677 citationsRCR 3.2